Patients v. Myriad or the GDPR Access Right v. the EU Database Right.

Area of Science:

• Genomic Medicine
• Bioethics
• Health Law

Background:

• Patients are increasingly seeking access to their comprehensive genomic data.
• Genetic testing companies may restrict access to data, citing proprietary rights.
• Existing regulations like HIPAA and the EU GDPR are being tested by these access demands.

Purpose of the Study:

• To analyze the legal basis for patients' access to genomic data.
• To examine the implications of the EU General Data Protection Regulation (GDPR) on genetic data access.
• To assess the potential impact on personalized medicine and genetic testing companies.

Main Methods:

• Legal analysis of patient claims under the Health Insurance Portability and Accountability Act (HIPAA).
• Examination of the EU GDPR's right of access in the context of genetic testing.
• Comparison of patient data rights against database rights.

Main Results:

• US patients asserted a right to access genomic data under HIPAA.
• The EU GDPR's right of access may not grant unconditional access to all testing data.
• Access may be limited if it violates medical norms, creates liability, or harms database exploitation.

Conclusions:

• Patient access to genomic data is a complex legal and ethical issue.
• The GDPR's application to genetic testing data requires careful consideration of competing rights.
• Balancing patient access with company incentives is crucial for the future of personalized medicine.